Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs

JERSEY CITY, N.J.–(BUSINESS WIRE)–Celltrion USA, Inc. (Celltrion USA) today announced its FDA-approved biosimilar, YUFLYMA® (adalimumab-aaty), has been added to CarePartners Specialty Pharmacy Cost Savings Programs. YUFLYMA is a high-concentration (100mg/mL) and citrate-free formulation of the Humira® (adalimumab) biosimilar. CarePartners and its strategic partners will offer and distribute YUFLYMA as the lowest net cost high-concentration Humira (adalimumab) biosimilar to over 10 million plan members.

Read Full Article

Leave a Reply

Your email address will not be published. Required fields are marked *

Join Our Mailing List

    CarePartners Pharmacy
    326 Peterson Rd.
    Libertyville, IL 60048
    Call Us:
    Mon-Fri 8:30am to 5:30pm CST
    Email us anytime:

    © 2022 CarePartners Pharmacy  |  Sitemap  |  HIPAA Privacy Notice  |  Privacy Policy  |  Terms & Conditions